Nexstim said today it launched its Navigated Brain Therapy transcranial magnetic stimulation system designed to treat major depressive disorder in the US, having won FDA approval for the device last November.
The Helsinki-based company announced the launch at the Clinical TMS Society’s annual meeting in New York.
“We are extremely pleased to announce the launch of our NBT system for depression at this TMS focused event. The unique navigational capability of our system, personalized to each patient for targeted stimulation of the relevant brain area, clearly differentiates it from the non-navigational TMS devices currently on the market for this indication,” chair & CEO Martin Jamieson said in a press release.
Nexstim’s NBT therapy is designed as a personalized, non-invasive neurostimulation therapy for treating major depressive disorder, and as an alternative to sub-optimal pharmacologic treatments.
The company said it is expanding its US-based field organization to help support sales and service of the system, and is looking to establish a US TMS Therapy Clinical Advisory Panel to provide advice and feedback on the use of the system.
Last June, Nexstim said that the Finnish Funding Agency for Innovation agreed to extend the due date for repayment of two of its research & development project loans.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.